2024
Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children
Lo A, Liu A, Liu Q, Yasui Y, Castellino S, Kelly K, Hererra A, Friedberg J, Friedman D, Schwartz C, Pei Q, Kessel S, Bergeron-Gravel S, Dama H, Roberts K, Constine L, Hodgson D. Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children. JAMA Network Open 2024, 7: e2351062. PMID: 38241048, PMCID: PMC10799264, DOI: 10.1001/jamanetworkopen.2023.51062.Peer-Reviewed Original ResearchConceptsCardiac toxic effectsMediastinal RTHodgkin lymphomaRadiation therapyCumulative incidenceCardiac diseaseDoxorubicin doseCohort studyClinical trialsMedian mean heart doseChildren's Oncology Group clinical trialStudy populationHigh-risk HLMean heart dosePlanned cumulative doseRadiation therapy useIncidence of cardiac diseaseCumulative doxorubicin doseRisks associated with treatmentNorth American trialsGroup clinical trialFollow-up guidelinesStandard treatment groupToxic effectsMaintained long term
2023
Prognostic value of chest x‐ray‐ and CT‐defined large mediastinal adenopathy in high‐risk pediatric Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0831
Lo A, Lee I, Pei Q, Wu Y, McCarten K, Hoppe B, Hodgson D, Roberts K, Milgrom S, Kessel S, Cole P, Kelly K, Cho S. Prognostic value of chest x‐ray‐ and CT‐defined large mediastinal adenopathy in high‐risk pediatric Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0831. Pediatric Blood & Cancer 2023, 70: e30452. PMID: 37243975, PMCID: PMC10546608, DOI: 10.1002/pbc.30452.Peer-Reviewed Original ResearchConceptsRelapse-free survivalLarge mediastinal adenopathySlow early responseInferior relapse-free survivalWorse relapse-free survivalMediastinal mass ratioPediatric Hodgkin lymphomaHodgkin's lymphomaMediastinal adenopathyPrognostic valueAdvanced-stage HL patientsChildren's Oncology Group studyChest X-rayHazard ratioHL patientsMedian agePoor prognosisChest radiographsMass volumeMass diameterPatientsML/Group studyCTEarly responseRadiation Therapy Use in Refractory and Relapsed Adolescent and Young Adult Hodgkin Lymphoma: A Report from the Children's Oncology Group
Mailhot Vega R, Harker-Murray P, Forlenza C, Cole P, Kelly K, Milgrom S, Parikh R, Hodgson D, Castellino S, Kahn J, Roberts K, Constine L, Hoppe B. Radiation Therapy Use in Refractory and Relapsed Adolescent and Young Adult Hodgkin Lymphoma: A Report from the Children's Oncology Group. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: 400-403. PMID: 37116589, PMCID: PMC10655744, DOI: 10.1016/j.ijrobp.2023.04.022.Peer-Reviewed Original Research
2019
Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group
Kelly KM, Cole PD, Pei Q, Bush R, Roberts KB, Hodgson DC, McCarten KM, Cho SY, Schwartz C. Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group. British Journal Of Haematology 2019, 187: 39-48. PMID: 31180135, PMCID: PMC6857800, DOI: 10.1111/bjh.16014.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCyclophosphamideDoxorubicinDrug Administration ScheduleDrug MonitoringEtoposideFemaleHodgkin DiseaseHumansIfosfamideMaleNeoplasm StagingPositron-Emission TomographyPrednisoneProspective StudiesRadiotherapy, AdjuvantRecurrenceTreatment OutcomeVincristineVinorelbineYoung AdultConceptsHigh-risk Hodgkin lymphomaABVE-PCOncology GroupHodgkin's lymphomaEarly respondersRapid early respondersEnd of chemotherapyEvent-free survivalOverall survival rateResponse-adapted therapyChildren's Oncology GroupTreatment of childrenPET-positive lesionsAlkylator exposureOS ratesActive diseaseTreat analysisPediatric patientsRadiotherapy volumeClinical evidenceEarly progressionRadiation volumeRecent trialsPositive lesionsSER patients
2016
Adjuvant chemotherapy and overall survival in adult medulloblastoma
Kann BH, Lester-Coll NH, Park HS, Yeboa DN, Kelly JR, Baehring JM, Becker KP, Yu JB, Bindra RS, Roberts KB. Adjuvant chemotherapy and overall survival in adult medulloblastoma. Neuro-Oncology 2016, 19: 259-269. PMID: 27540083, PMCID: PMC5464064, DOI: 10.1093/neuonc/now150.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCerebellar NeoplasmsChemoradiotherapy, AdjuvantChemotherapy, AdjuvantCraniospinal IrradiationFemaleFollow-Up StudiesHumansMaleMedulloblastomaMiddle AgedNeoplasm StagingPrognosisRadiotherapy, AdjuvantSurvival RateYoung AdultConceptsGy craniospinal irradiationCraniospinal irradiationOverall survivalM0 patientsAdjuvant chemotherapyAdult MBMultivariable Cox proportional hazard modelingHigh-dose craniospinal irradiationNational Cancer Data BaseCox proportional hazard modelingSuperior overall survivalPlanned subgroup analysisMultivariable logistic regressionNational database analysisLog-rank testProportional hazard modelingPediatric medulloblastoma patientsCSI dosesPostoperative chemotherapySurgical resectionSurvival impactYear OSMultivariable analysisSubgroup analysisRisk factors
2014
ACR appropriateness Criteria® pediatric Hodgkin lymphoma
Terezakis SA, Metzger ML, Hodgson DC, Schwartz CL, Advani R, Flowers CR, Hoppe BS, Ng A, Roberts KB, Shapiro R, Wilder RB, Yunes MJ, Constine LS. ACR appropriateness Criteria® pediatric Hodgkin lymphoma. Pediatric Blood & Cancer 2014, 61: 1305-1312. PMID: 24616347, DOI: 10.1002/pbc.24983.Peer-Reviewed Original ResearchConceptsPediatric Hodgkin lymphomaHodgkin's lymphomaAppropriateness CriteriaAppropriateness of imagingACR Appropriateness CriteriaExpert panelMultidisciplinary expert panelRadiology Appropriateness CriteriaEvidence-based guidelinesCommon clinical scenariosSpecific clinical conditionsCurrent medical literaturePotential long-term effectsCurable malignancyExpert medical opinionClinical variantsClinical conditionsLong-term effectsAmerican CollegeClinical careTherapy needTreatment approachesGuideline developmentClinical scenariosLymphoma
2012
Historical Trends in the Use of Radiation Therapy for Pediatric Cancers: 1973-2008
Jairam V, Roberts KB, Yu JB. Historical Trends in the Use of Radiation Therapy for Pediatric Cancers: 1973-2008. International Journal Of Radiation Oncology • Biology • Physics 2012, 85: e151-e155. PMID: 23273995, PMCID: PMC3636568, DOI: 10.1016/j.ijrobp.2012.10.007.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBone NeoplasmsChildChild, PreschoolFemaleHodgkin DiseaseHumansInfantInfant, NewbornLeukemia, Myeloid, AcuteLymphoma, Non-HodgkinMaleNeoplasmsNeuroblastomaOsteosarcomaPrecursor Cell Lymphoblastic Leukemia-LymphomaRadiotherapyRetinoblastomaSEER ProgramSoft Tissue NeoplasmsTime FactorsUnited StatesWilms TumorYoung AdultConceptsUse of RTSoft tissue cancerNon-Hodgkin lymphomaRT useAcute lymphoblastic leukemiaAcute myeloid leukemiaRadiation therapyHodgkin's lymphomaLymphoblastic leukemiaMyeloid leukemiaWilms tumorBrain cancerNational Cancer Institute's SurveillanceExternal beam radiation therapyEnd Results (SEER) databasePercentage of patientsSEER 9 databaseBeam radiation therapyTumor RegistryInitial treatmentResults databaseCombination therapyDiagnosis groupsPediatric cancerJoint cancerPatterns of subsequent malignancies after Hodgkin lymphoma in children and adults
Omer B, Kadan‐Lottick N, Roberts KB, Wang R, Demsky C, Kupfer GM, Cooper D, Seropian S, Ma X. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. British Journal Of Haematology 2012, 158: 615-625. PMID: 22775513, DOI: 10.1111/j.1365-2141.2012.09211.x.Peer-Reviewed Original ResearchConceptsSecond malignant neoplasmsStandardized incidence ratiosSolid second malignant neoplasmsExtended field radiotherapyRecent treatment optionsLow-dose radiationSMN riskSubsequent malignanciesModality therapyIncidence ratiosHodgkin's lymphomaTreatment optionsMalignant neoplasmsSubgroup analysisCMT groupLower incidenceHigh riskGeneral populationAlkylator chemotherapyPatientsDose radiationRiskRadiotherapyChildrenAdults
2011
Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis
Buscariollo DL, Park HS, Roberts KB, Yu JB. Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis. Cancer 2011, 118: 4212-4219. PMID: 22213196, DOI: 10.1002/cncr.27373.Peer-Reviewed Original ResearchConceptsAtypical teratoid rhabdoid tumorMedian overall survivalOverall survivalRT useLandmark analysisRhabdoid tumorRare central nervous system malignanciesNational Cancer Institute's SurveillanceCentral nervous system malignanciesCox proportional hazards modelRole of radiotherapyEnd Results (SEER) databaseEnd Results analysisSignificant survival benefitProspective clinical trialsGross total resectionPatients ages 4Nervous system malignanciesImmortal time biasProportional hazards modelLong-term survivorshipAdjuvant radiotherapyInitial radiotherapyPrimary endpointInitial management
2007
Size matters: gastric pouch size correlates with weight loss after laparoscopic Roux-en-Y gastric bypass
Roberts K, Duffy A, Kaufman J, Burrell M, Dziura J, Bell R. Size matters: gastric pouch size correlates with weight loss after laparoscopic Roux-en-Y gastric bypass. Surgical Endoscopy 2007, 21: 1397-1402. PMID: 17332953, DOI: 10.1007/s00464-007-9232-x.Peer-Reviewed Original ResearchConceptsLaparoscopic Roux-en-Y gastric bypassPreoperative body mass indexExcess weight lossBody mass indexGastric pouch sizeRoux-en-Y gastric bypassPouch sizeGastric bypassWeight lossIncreased preoperative BMIMale genderSuccess of surgical therapyMean pouch sizePostoperative day 1ResultsThe mean ageYale-New Haven HospitalUpper gastrointestinal seriesProspective databaseSurgical therapyMorbid obesityStudy patientsBariatric surgeryNew Haven HospitalMean ageMass index
2000
Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy
Elconin J, Roberts K, Rizzieri D, Vermont C, Clough R, Kim C, Dodge R, Prosnitz L. Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy. International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 1097-1105. PMID: 11072168, DOI: 10.1016/s0360-3016(00)00695-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleHodgkin DiseaseHumansMaleMechlorethamineMediastinal NeoplasmsMiddle AgedNeoplasm StagingPrednisoneProcarbazineRadiotherapy DosageRetrospective StudiesTreatment FailureVinblastineVincristineConceptsLarge mediastinal adenopathyHodgkin's disease patientsComplete responseDisease patientsInduction chemotherapyInduction failureGallium scanMediastinal adenopathyModality therapyRT doseComplete clinical stagingLow-dose radiotherapyResidual radiographic abnormalitiesCycles of chemotherapyFailure-free survivalPhase III trialsPatterns of failureConsolidation radiationChemotherapy regimensCR patientsIII trialsOverall survivalClinical stagingHD patientsRadiographic abnormalities
1999
Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia
Jillella A, Doria R, Khan K, Zelterman D, Ahmad Y, Smith B, Holmes W, Becker P, Roberts K, Rappeport J. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia. Bone Marrow Transplantation 1999, 23: 1095-1100. PMID: 10382947, DOI: 10.1038/sj.bmt.1701786.Peer-Reviewed Original ResearchConceptsAllogeneic bone marrow transplantationTotal body irradiationBone marrow transplantationConditioning regimenMarrow transplantationMyeloablative regimenRelapse rateBody irradiationHematologic malignanciesAntileukemic effectGood prognosis diseaseHigh-dose cytosineHost disease (GVHD) prophylaxisShort-course methotrexateEvidence of diseaseOverall relapse rateHigh-dose AraPoor prognosis diseaseKaplan-Meier estimatesActuarial survivalConditioning regimensDisease prophylaxisMyeloablative regimensProspective studyRegimen
1996
Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation.
Salloum E, Doria R, Schubert W, Zelterman D, Holford T, Roberts K, Farber L, Kiehl R, Cardinale J, Cooper D. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. Journal Of Clinical Oncology 1996, 14: 2435-43. PMID: 8823321, DOI: 10.1200/jco.1996.14.9.2435.Peer-Reviewed Original ResearchConceptsOverall relative riskHodgkin's diseaseRT groupRelative riskSolid tumorsCMT groupRadiation therapyLung cancerBreast cancerEarly-stage Hodgkin's diseaseFull-dose radiation therapyInvolved-field radiationSecond solid tumorsConnecticut Tumor RegistryEarly-stage diseaseLong-term survivorsDifferent therapeutic approachesCases of lungLow-dose radiationSignificant increaseActuarial incidenceMedian followSalvage chemotherapyAdvanced diseaseDurable remissions
1995
Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
Salloum E, Doria R, Farber L, Roberts K, Cooper D. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study. The Cancer Journal 1995, 1: 267-73. PMID: 9166487.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleFollow-Up StudiesHodgkin DiseaseHumansMaleMechlorethamineMiddle AgedNeoplasm Recurrence, LocalNeoplasms, Second PrimaryPrednisoneProcarbazineRemission InductionSalvage TherapyTime FactorsTreatment OutcomeVinblastineVincristineConceptsFailure-free survivalStage IV diseaseAdvanced Hodgkin's diseaseDisease-free survivalHodgkin's diseaseComplete remissionSecond malignanciesRadiation therapyLong-term disease-free survivalInvolved-field radiation therapyDurable second remissionsMOPP/ABVDRecurrent Hodgkin's diseaseInitial complete remissionCombined modality therapyMonths of chemotherapyLong-term resultsResults of treatmentSalvage therapySecond remissionInitial remissionUntreated patientsModality therapyOverall survivalChemotherapy program